Vaxart

Aviragen Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for serious infectious diseases. The company is advancing two Phase 2 clinical-stage candidates: laninamivir octanoate for the treatment of influenza A and B infections, supported by a substantial contract with the U.S. Office of Biomedical Advanced Research and Development Authority, and vapendavir, an oral broad-spectrum capsid inhibitor targeting enteroviruses, particularly human rhinovirus. Additionally, Aviragen is engaged in preclinical programs aimed at developing treatments for respiratory syncytial virus (RSV) and is exploring oral therapies for human rhinovirus infections in patients with moderate-to-severe asthma, as well as topical antiviral treatments for conditions caused by human papillomavirus.